Qiagen N.V. · NYSE:QGEN

Qiagen — Digene — Merger or Acquisition (June 2007)

32 slides from Qiagen's merger presentation, Jun 4, 2007

  1. Slide 1: QIAGEN - Sample & Assay Technologies / DIGENE Investor Call

    Filed by: QIAGEN N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14d-2 under the Securities Exchange Act of 1934 Subject Company: Digene Corporation Exchange Act File No. 000-28194 June Conference 1. Joe 2. QIAGEN -Sample 130 -P.4, min Slattery, 2007, &Q&

  2. Slide 2: Safe Harbor

    Joint Remarks outcomes recent addition income,” non-GAAP especially diluted In regulatory assays QIAGEN -Sample 2the - Safe attached filings and EPS, &to that “adjusted /to Harbor Assay when framework. 98 the DIGENE measures differ income with we general financial presentation, comparing Technologie

  3. Slide 3: Transaction Overview

    Transaction Purchase .Pro -Creating Transaction Timing Management: Customary Financing: 3 -formaof Value Price: Consideration: Ownership: Closing: Overview Stock, Approvals: Structure: for Peer US$DIGENE surplus Schatz, Expected 61.25 QIAGEN: Exchange Tender DIGENE cash, per QIAGEN andAugust/Septemb

  4. Slide 4: QIAGEN at a Glance

    Sample 550 Operating 2003 Revenues US$ DIGENE QIAGEN World’s Venlo, Listings: Market Founded: Headquarters: Employees: Rev -Listing: 4 - 500 2006 millions 2004 NLleader &NASDAQ: leading 450 NASDAQ: figures 1984 1987 /(US$ and CAGR Assay income 2005 DIGENE 1,990 570 400 DIGENE in Hilden, Gaithersburg

  5. Slide 5: DIGENE Overview

    Overview The Exclusive Regulatory Focus Portfolio HPV Chlamydia Blood Proprietary Headquartered Leader in QIAGEN -Sample 5Critical - DIGENE® (aon viruses in & run-rate includes women’s key Molecular /of IP Area Assay DIGENE and leadership Hybrid DIGENE positions segment such in gonorrhea of HPV of T

  6. Slide 6: A Decade-Long Partnership

    10+ Example: Core FDA-listed Co-developed DIGENE Over Next Partnership QIAGEN -Sample 6 - year platform generation 100&partnership products sole instruments Rapid /and Assay DIGENE instrument – Similar DIGENE marketer and ofplatform Capture® Technologies DIGENE manufactured integrate between Investo

  7. Slide 7: The Highly Significant Combination

    The Highly Significant Adds Next DIGENE QIAGEN’s QIAGEN -Sample 7 - Combination generation key attractive &can assay sample /Assay DIGENE premium combined unparalleled broad global Breadth utilize technologies platform Technologies consideration technologies Accelerates assay sales and QIAGEN’s and

  8. Slide 8: The Same Superb Combination

    The Same Superb Over DIGENE’s HPV Unique Great Enhanced QIAGEN’s QIAGEN -Sample 8 - Combination testing bridges $1 fit target brands regulatory &billion with /growth Assay DIGENE highly strong strategy: Breadth customers isQIAGEN’s QIAGEN’s and the market Technologies Accelerates profile IP focused

  9. Slide 9: The Market Value Combination

    The Market VALUE Targeting Unique Leader Industry Over Excellent Truly Leading Expanded World-class Compelling Enhanced Increased QIAGEN’s QIAGEN Sample -* 9Ex - Combination blood $350 300 1,000 global in and technology &in technologies leading professionals foundation > HPV combined /growth Assay o

  10. Slide 10: Highly Synergistic Capabilities and Assets

    Run-rateSynergistic Highly QIAGEN Sales DIGENE as ofCapabilities Q1 '07 and Assets Sales in MDx 512 210 (approximately) 154 210 Sales strength Sales force in MDx Global North America (approximately) 150 170 Sales force target in MDx Clinical Laboratories, Clinical Laboratories Physicians Assay porto

  11. Slide 11: Combined Revenue Highly Complementary

    Combined All By figures Revenue Product are estimates Groups Distribution + – Highly Complementary Based on Q1 2007 Consumables Consumables Consumables 89% 92% 90% Instruments Instruments Instruments 8% 10% By Customer Groups AT 10% AT MDx 11% MDx 8% 27% Research MDx 48% 20% Research 100% Pharma 27%

  12. Slide 12: Cervical Cancer: A Critical Disease

    A12 Cervical WW In One HPV The Extensive Medical Well Strong Pool Prevalence QIAGEN -Sample Critical the DIGENE -woman of established over isUS partnerships the “eligible” &community cancer /almost 470K Disease and Assay DIGENE proven ofdies HPV expanding is cases/year reimbursement Technologies eve

  13. Slide 13: DIGENE Cervical HPV Test

    DIGENE Cervical 1/3 The Clinical First ACOG Cites Combined HPV QIAGEN -Sample 13of DIGENE -FDA-approval testing Screening studies cervical Guidelines & practice results cancer HPV /Assay HPV DIGENE sensitivity showing HPV cancers Test published Can is testing guidelines Technologies more cites Test

  14. Slide 14: Significant Untapped U.S. Potential for HPV Testing

    Significant Untapped U.S. Potential for HPV Testing Current tests: Penetration rate: ~8.4M Europe ~22% Current tests: Penetration rate: ~2.0M Asia/Latin America: ~6% Current tests: Penetration rate: 0.9M Increasing Vaccine New Increased Significant Europe Asia/Latin million ~ Total: Substantial QIAG

  15. Slide 15: Vaccines and HPV Testing Growth Driver

    Significant Approved Target It Limited Vaccinations DIGENE Vaccine Experience Duration Possibility Vaccines QIAGEN -Sample 15 would - testing age vaccination &efficacy to take Are are of HPV /Assay vaccination groups 2of DIGENE marketing effectiveness “high aa>20 genotype age: Compelling Test Compel

  16. Slide 16: Tangible Future Growth Synergies

    Tangible Multiplexing Next-generation Assay Exciting Manufacturing Channel FastHPV Next And Significant QIAGEN -Sample 16 -many generation breadth preparation &lends near-term other Opportunities platform /is Assay more DIGENE Growth key technologies synergies in itself capacity instrumentation supp

  17. Slide 17: Companies Are Direct Neighbors

    Companies QIAGEN -Sample 17 - & /and Assay DIGENE areDIGENE 5 Technologies minutes Investor - -apart Direct Call, (2.8 Neighbors June miles) 4, 2007 Germantown and Gaithersburg MD

  18. Slide 18: World-Class Integration Plan

    World-Class Great Leading Similar Strong Integration 12 Mirrored Being Maryland: Significant QIAGEN -Sample 18month - management neighbors leaders foundation synergies cultures &expertise teams process, /has Assay U.S. DIGENE plan Growth Capabilities proven from Headquarters well-developed and aTech

  19. Slide 19: Consistent Strategy and Transaction Rationale

    A19 Consistent QIAGEN: DIGENE: Channel Content Technology Transaction Management Significant Participation Attractive Combined Excellent Most Infrastructure Creating QIAGEN -Sample New - exciting Leader &/Value abasis /Infrastructure Assay earnings aleadership new entity with DIGENE premium provides

  20. Slide 20: Financial Rationale

    Financial Enhancing Cost Accretive Significantly Strong Revenue QIAGEN -Sample 20 -synergy cash &Enhancing synergy Rationale /to Assay revenue DIGENE flow adjusted accretive opportunities Technologies generation opportunities and -Investor EPS Accretive toEPS 2009 in growth the Call, EPS –first Cash

  21. Slide 21: Continuous Double Digit Revenue Growth

    US$ CAGR DIGENE -QIAGEN Sample 21 -millions Total Q D&revenues 2003-2006 +Assay revenues /– DIGENE Continuous DIGENE 2003-2006 Technologies converted excluding Investor =Revenue 15% 32% Double = 19% to the Call, Growth Digit calendar synthetic June Revenue 2003 4,year 2007 DNA –(CY) 2007E Growth bus

  22. Slide 22: Strongly Benefits from Synergies: Operating Income

    US$ CAGR 1. DIGENE -QIAGEN Sample 22 Operating -millions Total Q D&net 2003-2006 +Assay /– DIGENE Operating DIGENE income 2003-2006 income Technologies excludes Investor = converted Operating Income 17% 235% = 25%Call, acquisition, Strongly toIncome CY JuneBenefits 4, 2003 integration 2007 – 2007E1

  23. Slide 23: Accelerating Earnings Development: Net Income

    US$ DIGENE CAGR 1. CY -QIAGEN Sample 23 Net -millions income Total Q D&2003-2006 +Assay /– DIGENE Accelerating DIGENE 2003-2006 excludes Technologies Investor =Net 22% 157% acquisition, =Earnings Income 31%Call,2003 Development June integration –4,2007E1 2007and relocation related charges as well as

  24. Slide 24: Sustainable Synergy Cost Savings

    Synergy Cost Savings Sustainable Eliminated Augmented Expanded Further Revenue Geographic Product Integration Douglas Thomas Joe Doug -QIAGEN Sample 24Slattery, -synergies White, synergies & synergies of Schweins, Opportunities Liu, synergies sales /track Assay applicability US$35 DIGENE project red

  25. Slide 25: Contribution to Fiscal Year 2007

    Q4 2007 and Contribution Q3 Assumes Revenue Expected current adj.to EPS EPS1 Fiscal consensus allocation forYear the third 2007 estimates dependent quarter foron approx. DIGENE final closing US$ (0.01) date – (0.02) Net sales, US$ m2 Adj. EPS, US$1 58 - 60 1.25 2. -QIAGEN Sample Adjusted Based - &up

  26. Slide 26: Contribution and Accretion to Fiscal Year 2008

    Net figures Contribution All sales, US$ reflect andm Accretion calendar year to Fiscal estimates Year 2008 Synergy revenues FY 2602008 - 270 Instrument and other product sales to DIGENE + Net sales, US$ m - Adj. Operating margin1 260 - 270 Adj. EPS, US$1 28% - 30% 0.02 – 0.04 1.26 Significantly QIAG

  27. Slide 27: Combined Strong Financial Strength

    Combined Equity Strong Cash EBITDA Mid 1. -QIAGEN Sample 27 Adjusted -term flow ratio: balance cash &2008: outlook /Assay in Financial DIGENE EPS flow >2008: 45 sheet >excludes Technologies generation US$250 /%strong >Strength Investor US$100 acquisition, margin million Call, million improvement Jun

  28. Slide 28: Transaction Roadmap

    Roadmap Commence Queen HSR Complete Transaction -QIAGEN Sample 28 -approval shareholder & /to Tender Assay DIGENE exchange close Completion Technologies Offer expected vote Investor offer in early August/September forCall, both JulyJune cash 4, and2007 stock 2007in June

  29. Slide 29: Transaction Highlights

    Transaction Creation QIAGEN’s Unique Comprehensive Excellent World-class Substantial Significant Smooth Accretive Combination QIAGEN -Sample Expansion: New 29 - products/applications technology, &integration of foundation /to Assay DIGENE product growth breadth aHighlights capabilities adj. geograph

  30. Slide 30: Questions and Answers

    Questions QIAGEN -Sample 30 - & /Assay and DIGENE Answers Technologies Investor Call - June 4, 2007

  31. Slide 31: Disclaimer Regarding Forward-Looking Statements

    Disclaimer Regarding Forward-Looking Statements Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties. Such forward- looking statements include, but are not limited to, statements about the anticipated benefits of QIAGEN’s

  32. Slide 32: Additional Information on the Exchange Offer

    the exchange offer. These documents contain important information about the transaction and should be read before any decision is made with respect to the exchange offer. Investors and stockholders will be able to obtain free copies of these documents through the website maintained by the Securities

Digene — Merger or Acquisition (June 2007) on 6ix